Alethia Young
Stock Analyst at Cantor Fitzgerald
(3.68)
# 731
Out of 4,868 analysts
141
Total ratings
54.46%
Success rate
30.75%
Average return
Main Sectors:
Stocks Rated by Alethia Young
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCUS Arcus Biosciences | Reiterates: Overweight | n/a | $8.51 | - | 5 | Jul 5, 2024 | |
| ARWR Arrowhead Pharmaceuticals | Reiterates: Overweight | n/a | $15.62 | - | 5 | Jun 20, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $800 → $850 | $513.58 | +65.50% | 9 | Oct 16, 2023 | |
| ALXO ALX Oncology Holdings | Reiterates: Overweight | $18 | $0.49 | +3,599.90% | 6 | Sep 12, 2023 | |
| CRIS Curis | Reiterates: Overweight | $60 | $2.30 | +2,508.70% | 3 | Sep 7, 2023 | |
| ELDN Eledon Pharmaceuticals | Reiterates: Overweight | $9 | $2.78 | +223.74% | 2 | Aug 22, 2023 | |
| VSTM Verastem | Reiterates: Overweight | $34 | $5.19 | +555.11% | 2 | Jul 6, 2023 | |
| BIIB Biogen | Maintains: Neutral | $427 → $327 | $126.54 | +158.42% | 7 | Oct 15, 2021 | |
| ADVM Adverum Biotechnologies | Downgrades: Neutral | $230 → $30 | $2.29 | +1,212.91% | 4 | Jul 23, 2021 | |
| RAPT RAPT Therapeutics | Maintains: Overweight | $51 → $71 | $7.42 | +856.87% | 2 | Jun 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $285 → $281 | $448.40 | -37.33% | 5 | Jun 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $8 | $3.56 | +124.72% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $86 → $98 | $1.21 | +7,999.17% | 3 | Feb 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $280 → $295 | $289.63 | +1.85% | 9 | Feb 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $84 → $86 | $108.00 | -20.37% | 3 | Oct 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $48 | $35.17 | +36.50% | 4 | Oct 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $7.41 | +304.86% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $72 | $35.46 | +103.05% | 8 | Jul 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $5 | $1.31 | +281.68% | 5 | Jun 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $83 → $100 | $68.27 | +46.48% | 6 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $185 → $201 | $170.71 | +17.74% | 6 | Apr 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $86 → $85 | $50.43 | +68.55% | 5 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $32 | $7.92 | +304.04% | 1 | Mar 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $211 → $217 | $20.77 | +944.78% | 12 | Feb 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $75 → $48 | $23.39 | +105.22% | 4 | Oct 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $11.69 | - | 3 | Mar 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $151 → $154 | $312.32 | -50.69% | 5 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $113 → $116 | $55.24 | +109.99% | 2 | Mar 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $147 → $106 | $3.41 | +3,013.07% | 8 | Jan 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $28 | $9.60 | +191.67% | 1 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $85 → $82 | $222.75 | -63.19% | 2 | Sep 27, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | n/a | $291.72 | - | 1 | Mar 16, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.97 | - | 1 | Oct 18, 2016 |
Arcus Biosciences
Jul 5, 2024
Reiterates: Overweight
Price Target: n/a
Current: $8.51
Upside: -
Arrowhead Pharmaceuticals
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $15.62
Upside: -
Regeneron Pharmaceuticals
Oct 16, 2023
Maintains: Neutral
Price Target: $800 → $850
Current: $513.58
Upside: +65.50%
ALX Oncology Holdings
Sep 12, 2023
Reiterates: Overweight
Price Target: $18
Current: $0.49
Upside: +3,599.90%
Curis
Sep 7, 2023
Reiterates: Overweight
Price Target: $60
Current: $2.30
Upside: +2,508.70%
Eledon Pharmaceuticals
Aug 22, 2023
Reiterates: Overweight
Price Target: $9
Current: $2.78
Upside: +223.74%
Verastem
Jul 6, 2023
Reiterates: Overweight
Price Target: $34
Current: $5.19
Upside: +555.11%
Biogen
Oct 15, 2021
Maintains: Neutral
Price Target: $427 → $327
Current: $126.54
Upside: +158.42%
Adverum Biotechnologies
Jul 23, 2021
Downgrades: Neutral
Price Target: $230 → $30
Current: $2.29
Upside: +1,212.91%
RAPT Therapeutics
Jun 14, 2021
Maintains: Overweight
Price Target: $51 → $71
Current: $7.42
Upside: +856.87%
Jun 11, 2021
Maintains: Overweight
Price Target: $285 → $281
Current: $448.40
Upside: -37.33%
Mar 8, 2021
Initiates: Overweight
Price Target: $8
Current: $3.56
Upside: +124.72%
Feb 25, 2021
Maintains: Overweight
Price Target: $86 → $98
Current: $1.21
Upside: +7,999.17%
Feb 3, 2021
Maintains: Overweight
Price Target: $280 → $295
Current: $289.63
Upside: +1.85%
Oct 29, 2020
Reiterates: Overweight
Price Target: $84 → $86
Current: $108.00
Upside: -20.37%
Oct 28, 2020
Maintains: Overweight
Price Target: $30 → $48
Current: $35.17
Upside: +36.50%
Oct 12, 2020
Initiates: Overweight
Price Target: $30
Current: $7.41
Upside: +304.86%
Jul 31, 2020
Maintains: Overweight
Price Target: $70 → $72
Current: $35.46
Upside: +103.05%
Jun 2, 2020
Assumes: Overweight
Price Target: $5
Current: $1.31
Upside: +281.68%
May 19, 2020
Maintains: Neutral
Price Target: $83 → $100
Current: $68.27
Upside: +46.48%
Apr 20, 2020
Reiterates: Overweight
Price Target: $185 → $201
Current: $170.71
Upside: +17.74%
Apr 8, 2020
Reiterates: Overweight
Price Target: $86 → $85
Current: $50.43
Upside: +68.55%
Mar 6, 2020
Maintains: Overweight
Price Target: $30 → $32
Current: $7.92
Upside: +304.04%
Feb 27, 2020
Reiterates: Overweight
Price Target: $211 → $217
Current: $20.77
Upside: +944.78%
Oct 3, 2019
Maintains: Neutral
Price Target: $75 → $48
Current: $23.39
Upside: +105.22%
Mar 22, 2018
Downgrades: Underperform
Price Target: n/a
Current: $11.69
Upside: -
Mar 13, 2018
Maintains: Outperform
Price Target: $151 → $154
Current: $312.32
Upside: -50.69%
Mar 2, 2018
Maintains: Outperform
Price Target: $113 → $116
Current: $55.24
Upside: +109.99%
Jan 24, 2018
Maintains: Outperform
Price Target: $147 → $106
Current: $3.41
Upside: +3,013.07%
Nov 3, 2017
Maintains: Outperform
Price Target: $24 → $28
Current: $9.60
Upside: +191.67%
Sep 27, 2017
Maintains: Neutral
Price Target: $85 → $82
Current: $222.75
Upside: -63.19%
Mar 16, 2017
Initiates: Underperform
Price Target: n/a
Current: $291.72
Upside: -
Oct 18, 2016
Initiates: Outperform
Price Target: n/a
Current: $1.97
Upside: -